Inozyme Pharma Appoints Petra Duda As Chief Medical Officer

May 15, 2025•2 months ago

Position

Chief Medical Officer

Company

Inozyme Pharma

Petra Duda

BostonTherapeuticsPharmaceuticalHealth Care

Description

Inozyme Pharma has appointed Petra Duda as its new Chief Medical Officer, succeeding the retiring Kurt Gunter. Dr. Duda brings over two decades of experience in global clinical development and regulatory leadership to the role.

Company Information

Company

Inozyme Pharma

Location

Boston, Massachusetts, United States

About

Inozyme Pharma is a clinical-stage biopharmaceutical company, with approximately 50 employees based in Boston. The company is dedicated to developing innovative therapeutics that target the PPi-Adenosine Pathway, a key regulator of bone health and blood vessel function. Disruptions in this pathway underlie a range of severe diseases, including ENPP1 Deficiency. Our lead investigational therapy, INZ-701, is an ENPP1 Fc fusion protein enzyme replacement therapy designed to restore pyrophosphate and adenosine levels. INZ-701 is currently in late-stage clinical development in ENPP1 Deficiency, with the potential to expand into additional indications where deficiencies in the Pyrophosphate-Adenosine Pathway contribute to disease pathology, including ABCC6 Deficiency and calciphylaxis. Through our pioneering work, we aim to transform treatment options for patients affected by these devastating conditions.

Executive Insights

Based on hiring data

New executive impact window

87% of new executives make significant technology decisions within first 100 days

Budget influence

C-level executives control 73% of technology spending decisions

Transformation catalyst

65% of new senior hires launch digital transformation initiatives

Vendor review timeline

New executives typically review existing vendors within 6 months

Related People

Petra hidden